The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Amgen, et al seeks to protect the lifeblood of their bottom line by recruiting a vulnerable patient group to do their lobbying for them. CMS is trying to follow the FDA in protecting patients and limiting inappropriate use of lifesaving but expensive (and sometimes dangerous) medicines.
These results are encouraging for ranexa. Ranexa has been a niche drug until now. There are so many therapies for angina, that it is rare for a patient to be refractory to standard therapy. I am a practicing cardiologist and I can only recall using this drug on one patient to date. ...
Current standard is plavix, aspirin, and IIbIIIa inhibitor or/and bivalrudin/lovenox/heparin in the setting of acute coronary syndrome(threatened MI) requiring intervention. It is no surprise that Integrillin plus plavix works better than plavix alone to inhibit platelets, since they inhibit...
The MERLIN TIMI-36 trial is the largest RCT of Ranexa to date - the size and scope of which would be expected to provide definitive data regarding this drug. Initial results for the entire enrolled patient population found no benefit (but no danger) from the drug. With such a large trial,...
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
This trial shows the value of this previously underrated drug. Pts with elevated bnp are at higher risk than those who do not have elevated levels. These are specifically the patients that need the most aggressive medical therapy and usually fall short on conventional treatment.
The devil is in the details! Far from disappointing, the protocol ammendments (dosing) based on pharmacokinetic analysis that have been effected are both prudent and reassuring. Prasugrel dosing is likely being adjusted to reflect its metabolism in various patient populations including the elderly and...
There is no reason to believe that prasugrel will be coming any time soon. While Dr. Ware may not have given the reasons for the suspension of the trials, the only reason to stop enrollment in a study of healthy volunteers is safety, as there is no efficacy end point. The only safety endpoint...